NASDAQ:SRPT Sarepta Therapeutics (SRPT) Stock Price, News & Analysis → One trade. One ticker. One week. (From Wealthpin Pro) (Ad) Free SRPT Stock Alerts $117.12 +0.16 (+0.14%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$117.06▼$119.9150-Day Range$115.62▼$141.5352-Week Range$55.25▼$159.89Volume440,864 shsAverage Volume977,215 shsMarket Capitalization$11.00 billionP/E RatioN/ADividend YieldN/APrice Target$158.38 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Sarepta Therapeutics alerts: Email Address Sarepta Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside35.2% Upside$158.38 Price TargetShort InterestHealthy4.90% of Shares Sold ShortDividend StrengthN/ASustainability-1.65Upright™ Environmental ScoreNews Sentiment0.56Based on 9 Articles This WeekInsider TradingSelling Shares$2.74 M Sold Last QuarterProj. Earnings Growth273.71%From $2.13 to $7.96 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.88 out of 5 starsMedical Sector34th out of 910 stocksPharmaceutical Preparations Industry12th out of 426 stocks 4.4 Analyst's Opinion Consensus RatingSarepta Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 12 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageSarepta Therapeutics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 4.0 Short Interest Percentage of Shares Shorted4.90% of the outstanding shares of Sarepta Therapeutics have been sold short.Short Interest Ratio / Days to CoverSarepta Therapeutics has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Sarepta Therapeutics has recently decreased by 7.44%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSarepta Therapeutics does not currently pay a dividend.Dividend GrowthSarepta Therapeutics does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSarepta Therapeutics has received a 62.32% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Neuromuscular disorders medication", "Clinical research services", and "Preclinical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Sarepta Therapeutics is -1.65. Previous Next 2.0 News and Social Media Coverage News SentimentSarepta Therapeutics has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Sarepta Therapeutics this week, compared to 9 articles on an average week.Search InterestOnly 17 people have searched for SRPT on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.MarketBeat FollowsOnly 9 people have added Sarepta Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -10% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sarepta Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,739,419.00 in company stock.Percentage Held by InsidersOnly 7.40% of the stock of Sarepta Therapeutics is held by insiders.Percentage Held by Institutions86.68% of the stock of Sarepta Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Sarepta Therapeutics are expected to grow by 273.71% in the coming year, from $2.13 to $7.96 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sarepta Therapeutics is -19.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sarepta Therapeutics is -19.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSarepta Therapeutics has a P/B Ratio of 12.74. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Sarepta Therapeutics Stock (NASDAQ:SRPT)Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.Read More SRPT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SRPT Stock News HeadlinesApril 20, 2024 | americanbankingnews.comWilliam Blair Analysts Decrease Earnings Estimates for Sarepta Therapeutics, Inc. (NASDAQ:SRPT)April 19, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Elevance Health (ELV), Sarepta Therapeutics (SRPT) and Intuitive Surgical (ISRG)April 23, 2024 | Wealthpin Pro (Ad)One trade. One ticker. One week. Do you want to target weekly income of up to $2k or more… Starting with just $500... With just one trade per week? April 15, 2024 | nasdaq.comRSI Alert: Sarepta Therapeutics (SRPT) Now OversoldApril 13, 2024 | finance.yahoo.com10 Unstoppable Stocks That Will Make You RicherApril 11, 2024 | seekingalpha.comPfizer: The Market Is WrongApril 11, 2024 | seekingalpha.comSarepta Therapeutics: Growth Trajectory Alters Trading StrategyApril 10, 2024 | markets.businessinsider.comSarepta Therapeutics: A Buy Recommendation Amidst Undervaluation and Growth Potential for ElevidysApril 23, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.April 8, 2024 | seekingalpha.comSarepta Therapeutics: Another 'Hold' Call Ahead Of Some Key CatalystsApril 8, 2024 | finance.yahoo.comWhy Sarepta's First-Quarter Report Is Already Dead In The Water: AnalystApril 7, 2024 | msn.comRBC sees Sarepta's Elevidys remaining on market: reportApril 6, 2024 | fool.com2 Biotech Stocks to Buy Hand Over Fist in AprilApril 5, 2024 | markets.businessinsider.comBuy Rating on Sarepta Therapeutics Amidst Anticipated Drug Approval and Market PotentialMarch 29, 2024 | businesswire.comSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 26, 2024 | bizjournals.comTrial results for Dravet drug spurs stock surge at Bedford biotechMarch 25, 2024 | finance.yahoo.comA Comprehensive Look at Sarepta's Growth and InnovationMarch 19, 2024 | ca.finance.yahoo.comSRPT Jun 2024 80.000 callMarch 13, 2024 | markets.businessinsider.comBuy Rating for Sarepta Therapeutics Amidst Promising Developments and Strategic PartnershipsMarch 13, 2024 | fool.comDoes This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?March 12, 2024 | finance.yahoo.comDirector Wigzell Hans Lennart Rudolf Sells 15,000 Shares of Sarepta Therapeutics Inc (SRPT)March 9, 2024 | uk.finance.yahoo.comSRPT Mar 2024 80.000 putMarch 8, 2024 | fool.comGot $1,000? Buy These Hot Growth Stocks Before They Take Off.March 7, 2024 | finance.yahoo.comDirector Stephen Mayo Sells 3,135 Shares of Sarepta Therapeutics Inc (SRPT)March 6, 2024 | markets.businessinsider.comSarepta Therapeutics’ Elevidys Poised for Market Leadership in DMD, Despite Emerging CompetitorsMarch 4, 2024 | fool.comSarepta Therapeutics Stock Has 73% Upside, According to 1 Wall Street AnalystMarch 4, 2024 | businesswire.comSarepta Therapeutics to Present at Upcoming Investor ConferencesSee More Headlines Receive SRPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today4/23/2024Next Earnings (Estimated)5/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SRPT Previous SymbolNASDAQ:AVII CUSIPN/A CIK873303 Webwww.sareptatherapeutics.com Phone(617) 274-4000Fax425-354-5038Employees1,314Year Founded1980Price Target and Rating Average Stock Price Target$158.38 High Stock Price Target$224.00 Low Stock Price Target$109.00 Potential Upside/Downside+32.7%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)($6.12) Trailing P/E RatioN/A Forward P/E Ratio56.05 P/E GrowthN/ANet Income$-535,980,000.00 Net Margins-43.11% Pretax Margin-41.83% Return on Equity-18.97% Return on Assets-4.65% Debt Debt-to-Equity Ratio1.32 Current Ratio3.95 Quick Ratio3.45 Sales & Book Value Annual Sales$1.24 billion Price / Sales9.02 Cash FlowN/A Price / Cash FlowN/A Book Value$9.19 per share Price / Book12.99Miscellaneous Outstanding Shares93,900,000Free Float86,951,000Market Cap$11.21 billion OptionableOptionable Beta0.94 Social Links 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Douglas S. Ingram Esq. (Age 61)President, CEO & Director Comp: $1.62MMr. Ian Michael Estepan (Age 48)Executive VP & CFO Comp: $917.53kDr. Louise R. Rodino-Klapac Ph.D. (Age 46)Executive VP, Chief Scientific Officer and Head of Research & Development Comp: $1.04MMr. Ryan E. Brown J.D. (Age 46)Executive VP, General Counsel & Corporate Secretary Comp: $823.36kMr. Bilal Arif (Age 52)Executive VP & Chief Technical Operations Officer Ms. Francesca T. NolanExecutive Director of Investor Relations and Corporate CommunicationsMs. Alison NasisiExecutive VP & Chief People OfficerDr. Diane L. Berry Ph.D.Executive VP and Chief of Global Policy & Advocacy OfficerMr. Dallan MurrayExecutive VP & Chief Customer OfficerMr. Will TiltonSenior VP, Head of Strategy & Chief of StaffMore ExecutivesKey CompetitorsUnited TherapeuticsNASDAQ:UTHRCatalentNYSE:CTLTDr. Reddy's LaboratoriesNYSE:RDYKaruna TherapeuticsNASDAQ:KRTXBeiGeneNASDAQ:BGNEView All CompetitorsInsiders & InstitutionsSapient Capital LLCSold 131 shares on 4/23/2024Ownership: 0.011%PFG Investments LLCBought 4,610 shares on 4/22/2024Ownership: 0.026%Altfest L J & Co. Inc.Bought 2,691 shares on 4/22/2024Ownership: 0.003%Handelsinvest InvesteringsforvaltningSold 1,069 shares on 4/19/2024Ownership: 0.002%Hudson Capital Management LLCBought 1,700 shares on 4/19/2024Ownership: 0.002%View All Insider TransactionsView All Institutional Transactions SRPT Stock Analysis - Frequently Asked Questions Should I buy or sell Sarepta Therapeutics stock right now? 15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last twelve months. There are currently 3 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" SRPT shares. View SRPT analyst ratings or view top-rated stocks. What is Sarepta Therapeutics' stock price target for 2024? 15 brokers have issued twelve-month price targets for Sarepta Therapeutics' stock. Their SRPT share price targets range from $109.00 to $224.00. On average, they predict the company's stock price to reach $158.38 in the next year. This suggests a possible upside of 35.2% from the stock's current price. View analysts price targets for SRPT or view top-rated stocks among Wall Street analysts. How have SRPT shares performed in 2024? Sarepta Therapeutics' stock was trading at $96.43 on January 1st, 2024. Since then, SRPT shares have increased by 21.5% and is now trading at $117.12. View the best growth stocks for 2024 here. When is Sarepta Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024. View our SRPT earnings forecast. How were Sarepta Therapeutics' earnings last quarter? Sarepta Therapeutics, Inc. (NASDAQ:SRPT) announced its earnings results on Wednesday, February, 28th. The biotechnology company reported $0.47 earnings per share for the quarter, topping analysts' consensus estimates of ($0.03) by $0.50. The biotechnology company had revenue of $396.80 million for the quarter, compared to analyst estimates of $387.18 million. Sarepta Therapeutics had a negative trailing twelve-month return on equity of 18.97% and a negative net margin of 43.11%. Sarepta Therapeutics's revenue was up 53.6% on a year-over-year basis. During the same period in the prior year, the firm posted ($1.24) EPS. What ETFs hold Sarepta Therapeutics' stock? ETFs with the largest weight of Sarepta Therapeutics (NASDAQ:SRPT) stock in their portfolio include Simplify Health Care ETF (PINK), Morningstar US Small Growth (MSGR), iShares Genomics Immunology and Healthcare ETF (IDNA), iShares Neuroscience and Healthcare ETF (IBRN), Global X Genomics & Biotechnology ETF (GNOM), Virtus LifeSci Biotech Products ETF (BBP), Principal Healthcare Innovators ETF (BTEC) and VanEck Biotech ETF (BBH). What is Douglas S. Ingram's approval rating as Sarepta Therapeutics' CEO? 15 employees have rated Sarepta Therapeutics Chief Executive Officer Douglas S. Ingram on Glassdoor.com. Douglas S. Ingram has an approval rating of 95% among the company's employees. This puts Douglas S. Ingram in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Sarepta Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sarepta Therapeutics investors own include Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV) and Walt Disney (DIS). Who are Sarepta Therapeutics' major shareholders? Sarepta Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.28%), PFG Investments LLC (0.03%), Sapient Capital LLC (0.01%), Wealth Enhancement Advisory Services LLC (0.01%), Sumitomo Mitsui Trust Holdings Inc. (0.00%) and Atwood & Palmer Inc. (0.00%). Insiders that own company stock include Bilal Arif, Douglas S Ingram, Hans Lennart Rudolf Wigzell, Ian Michael Estepan, Kathryn Jean Boor, Louise Rodino-Klapac, Michael Andrew Chambers, Richard Barry and Stephen Mayo. View institutional ownership trends. How do I buy shares of Sarepta Therapeutics? Shares of SRPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Sarepta Therapeutics have any subsidiaries? The following companies are subsidiares of Sarepta Therapeutics: Eisai, Myonexus Therapeutics, ST International Holdings Two Inc., Sarepta Securities Corp., and Sarepta Therapeutics Three LLC.Read More This page (NASDAQ:SRPT) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithSHOCKING Crypto Leak…Crypto 101 Mediatop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingMan Who Predicted 2008: “This Will be Worse.”AltimetryUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeHow to camouflage a factory of 53,000 workersStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sarepta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
